Trends and Disparities in Asthma Biologic Use in the United States.

ABSTRACT:

Background

From 2003 to 2015, only 1 biologic was approved for the treatment of moderate to severe asthma in the United States. Since 2015, 4 new asthma biologics were approved by the US Food and Drug Administration.

Objective

To describe trends and disparities of asthma biologic use in the United States from 2003 to 2018.

Methods

We conducted a retrospective analysis using a cohort developed from the OptumLabs Data Warehouse. Prevalent and incident asthma biologic users were identified, and characteristics of users and nonusers were analyzed using regression analysis. Clinician prescribing behavior was described.

Results

Use of biologic medications remains uncommon among individuals with asthma, with prevalence peaking in 2006 at 3 in 1000 individuals with ast

SUBMITTER: Inselman JW 

PROVIDER: S-EPMC7012665 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature